| Symbol | GLSI |
|---|---|
| Name | GREENWICH LIFESCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3992 BLUEBONNET DRIVE,BUILDING 14, STAFFORD, Texas, 77477, United States |
| Telephone | +1 832 819-3232 |
| Fax | — |
| — | |
| Website | https://www.greenwichlifesciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001799788 |
| Description | Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels. Additional info from NASDAQ: |
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Read moreGreenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Read moreDirector Patel Snehal 🟢 acquired 2.2K shares of Greenwich LifeSciences, Inc. (GLSI) at $13.59 Transaction Date: Jul 28, 2026 | Filing ID: 035310
Read moreDirector Patel Snehal 🟢 acquired 1.5K shares of Greenwich LifeSciences, Inc. (GLSI) at $13.62 Transaction Date: Jul 27, 2026 | Filing ID: 035085
Read moreDirector Patel Snehal 🟢 acquired 3.6K shares of Greenwich LifeSciences, Inc. (GLSI) at $13.14 Transaction Date: Jul 23, 2026 | Filing ID: 034675
Read moreGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
Read moreGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
Read moreGreenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05232916 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 … | Phase3 | Breast Cancer | Recruiting | 2022-12-16 | 2031-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| GLSI-100 | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| GLSI-100 | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| GLSI-100 | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| Placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| GLSI-100 | BIOLOGICAL | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |
| Placebo | BIOLOGICAL | Phase PHASE3 | Breast Cancer | RECRUITING | NCT05232916 |